Shares Outstanding Shares Outstanding n/a Close	58.53M
Shares Change (YoY) Shares Change (YoY) n/a Close	-97.51%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	-4.25%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	62.63%
Shares Floating Shares Floating n/a Close	47.25M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	3,202
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.26%

Short Selling Information

The latest short interest is 11.82M, so 20.19% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	11.82M
Short % of Shares Out Short % of Shares Out n/a Close	20.19%
Short % of Float Short % of Float n/a Close	26.18%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	11.7

Valuation Ratios

The PE ratio is -0.93 and the forward PE ratio is -2.2. Ginkgo Bioworks's PEG ratio is 0.02.

PE Ratio PE Ratio n/a Close	-0.93
Forward PE Forward PE n/a Close	-2.2
PS Ratio PS Ratio n/a Close	2.24
Forward PS Forward PS n/a Close	1.3
PB Ratio PB Ratio n/a Close	0.71
P/FCF Ratio P/FCF Ratio n/a Close	-1.33
PEG Ratio PEG Ratio n/a Close	0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ginkgo Bioworks.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.65.

Current Ratio Current Ratio n/a Close	5.62
Quick Ratio Quick Ratio n/a Close	5.62
Debt / Equity Debt / Equity n/a Close	0.65
Debt / EBITDA Debt / EBITDA n/a Close	-0.97
Debt / FCF Debt / FCF n/a Close	-1.22
Interest Coverage Interest Coverage n/a Close	-5954.86

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$272,233.81
Profits Per Employee Profits Per Employee n/a Close	$-655,910.07
Employee Count Employee Count n/a Close	834
Asset Turnover Asset Turnover n/a Close	0.16
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	-479K
Effective Tax Rate Effective Tax Rate n/a Close	0.09%

Stock Price Statistics

The stock price has increased by -46.71% in the last 52 weeks. The beta is 1.26, so Ginkgo Bioworks's price volatility has been higher than the market average.

Beta Beta n/a Close	1.26
52-Week Price Change 52-Week Price Change n/a Close	-46.71%
50-Day Moving Average 50-Day Moving Average n/a Close	7.6
200-Day Moving Average 200-Day Moving Average n/a Close	8.58
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	61.9
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,234,857

Income Statement

In the last 12 months, Ginkgo Bioworks had revenue of 227.04M and earned -547.03M in profits. Earnings per share was -10.54.

Revenue Revenue n/a Close	227.04M
Gross Profit Gross Profit n/a Close	188.49M
Operating Income Operating Income n/a Close	-559.76M
Net Income Net Income n/a Close	-547.03M
EBITDA EBITDA n/a Close	-484.39M
EBIT EBIT n/a Close	-547.41M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-10.54

Full Income Statement

Balance Sheet

The company has 561.57M in cash and 467.73M in debt, giving a net cash position of 93.84M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	561.57M
Total Debt Total Debt n/a Close	467.73M
Net Cash Net Cash n/a Close	93.84M
Retained Earnings Retained Earnings n/a Close	-5.84B
Total Assets Total Assets n/a Close	1.29B
Working Capital Working Capital n/a Close	448.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -319.58M and capital expenditures -62.54M, giving a free cash flow of -382.13M.

Operating Cash Flow Operating Cash Flow n/a Close	-319.58M
Capital Expenditures Capital Expenditures n/a Close	-62.54M
Free Cash Flow Free Cash Flow n/a Close	-382.13M
FCF Per Share FCF Per Share n/a Close	-7.36

Full Cash Flow Statement

Margins

Gross margin is 83.02%, with operating and profit margins of -246.54% and -240.94%.

Gross Margin Gross Margin n/a Close	83.02%
Operating Margin Operating Margin n/a Close	-246.54%
Pretax Margin Pretax Margin n/a Close	-241.15%
Profit Margin Profit Margin n/a Close	-240.94%
EBITDA Margin EBITDA Margin n/a Close	-213.35%
EBIT Margin EBIT Margin n/a Close	-246.54%
FCF Margin FCF Margin n/a Close	-168.31%

Dividends & Yields

DNA does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for DNA is $10, which is 9.4% higher than the current price. The consensus rating is "Sell".

Price Target Price Target n/a Close	$10
Price Target Difference Price Target Difference n/a Close	9.4%
Analyst Consensus Analyst Consensus n/a Close	Sell
Analyst Count Analyst Count n/a Close	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:40.

Last Split Date Last Split Date n/a Close	Aug 20, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:40

Scores

Altman Z-Score Altman Z-Score n/a Close	-6.56
Piotroski F-Score Piotroski F-Score n/a Close	3